Table 5. The relationship between clinic-pathological characteristics of patients with ER-positive primary operable invasive ductal breast cancer and cancer-specific survival.

	Univariate survival analysis		Multivariate survival analysis
	HR (95% CI)	P -value	HR (95% CI)	P -value
Age (⩽50/>50 years)	2.21 (0.94–5.21)	0.070	2.84 (1.04–7.81)	0.043
Size (⩽20/21–50/>50 mm)	2.23 (1.37–3.62)	0.001		0.150
Grade (I/II/III)	1.93 (1.26–2.97)	0.003		0.109
Involved lymph node (0/1–3/>3)	2.47 (1.70–3.58)	<0.001	1.89 (1.18–3.03)	0.008
Progesterone-receptor status (PR−/PR+)	0.63 (0.35–1.15)	0.131
HER-2 status (HER-2−/HER-2+)	2.23 (0.99–4.96)	0.053	3.37 (1.34–8.47)	0.010
Ki-67 status (low Ki-67/high Ki-67)	4.19 (2.30–7.63)	<0.001	5.57 (2.73–11.36)	<0.001
Vascular invasion (absent/present)	4.42 (2.26–8.68)	<0.001	2.60 (1.11–6.10)	0.027
General inflammatory cell infiltrate (absent/present)	0.34 (0.16–0.72)	0.005	0.26 (0.09–0.72)	0.009
% Tumour lymphocyte infiltrate (low grade/high grade)	0.13 (0.07–0.26)	<0.001	0.15 (0.07–0.33)	<0.001
% Tumour plasma cell infiltrate (low grade/high grade)	3.53 (1.97–6.29)	<0.001		0.708
% Tumour other inflammatory cell infiltrate (low grade/high grade)	3.49 (1.77–6.89)	<0.001		0.171
Macrophage (tertiles 1, 2, 3)	0.92 (0.63–1.34)	0.647
Loco-regional treatment (Lumpectomy±radiotherapy/mastectomy±radiotherapy)	2.16 (1.12–4.18)	0.022		0.075
Systemic treatment (ER-based treatment; hormonal/hormonal+chemotherapy/chemotherapy/none)	1.18 (0.85–1.63)	0.328

Abbreviations: CI=confidence interval; ER=oestrogen receptor; HER-2=human epidermal growth factor receptor-2; HR=hazard ratio; PR=progesterone receptor.